RPTX (Repare Therapeutics) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 24, 2026)


RPTX Repare Therapeutics Inc RPTX
20 GF Score
Price $2.65
GF Value $0.94
! 6 Warning Signs
View Full Analysis

What is Repare Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Repare Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

RPTX vs MGNX, THAR, ANIX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Repare Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Repare Therapeutics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Repare Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Repare Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.


RPTX
20GF Score
Repare Therapeutics Inc RPTX
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Repare Therapeutics (RPTX) Overvalued in 2026?

Based on GuruFocus' analysis, Repare Therapeutics stock appears to be overvalued. The current stock price of $2.65 is trading 181.9% above its estimated GF Value™ of $0.94.

Key valuation signals for RPTX:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $0.94 vs. price of $2.65 (181.9% above fair value)
  • GF Score™: 20/100 with 6 warning signs

No single metric tells the full story. See the RPTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Repare Therapeutics Business Description

Address 7210 Frederick-Banting Street, Suite 100, Saint-Laurent, QC, CAN, H4S 2A1
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
20GF Score

Get the complete analysis for RPTX

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.65
Price
$0.94
GF Value